Analysts expect BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) to report earnings of ($0.28) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for BioCryst Pharmaceuticals’ earnings. The highest EPS estimate is ($0.25) and the lowest is ($0.33). BioCryst Pharmaceuticals posted earnings per share of ($0.26) in the same quarter last year, which indicates a negative year-over-year growth rate of 7.7%. The firm is scheduled to report its next earnings results on Tuesday, May 14th.
According to Zacks, analysts expect that BioCryst Pharmaceuticals will report full-year earnings of ($1.19) per share for the current fiscal year, with EPS estimates ranging from ($1.30) to ($1.09). For the next fiscal year, analysts anticipate that the firm will post earnings of ($1.15) per share, with EPS estimates ranging from ($1.35) to ($0.95). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that cover BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, March 4th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.01. BioCryst Pharmaceuticals had a negative net margin of 490.25% and a negative return on equity of 175.83%. The business had revenue of $2.73 million during the quarter, compared to analysts’ expectations of $2.39 million.
In other BioCryst Pharmaceuticals news, VP Lynne Powell sold 6,000 shares of BioCryst Pharmaceuticals stock in a transaction on Friday, January 25th. The shares were sold at an average price of $9.60, for a total transaction of $57,600.00. Following the completion of the transaction, the vice president now directly owns 6,000 shares of the company’s stock, valued at $57,600. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Thomas R. Staab II sold 5,000 shares of BioCryst Pharmaceuticals stock in a transaction on Monday, January 28th. The stock was sold at an average price of $9.85, for a total transaction of $49,250.00. Following the transaction, the chief financial officer now directly owns 133,426 shares of the company’s stock, valued at $1,314,246.10. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 32,500 shares of company stock valued at $308,725. Company insiders own 4.50% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in BCRX. Geode Capital Management LLC lifted its stake in BioCryst Pharmaceuticals by 9.7% in the fourth quarter. Geode Capital Management LLC now owns 1,227,763 shares of the biotechnology company’s stock valued at $9,908,000 after buying an additional 108,785 shares during the period. Amalgamated Bank acquired a new position in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $122,000. Legal & General Group Plc lifted its stake in BioCryst Pharmaceuticals by 14.5% in the fourth quarter. Legal & General Group Plc now owns 19,315 shares of the biotechnology company’s stock valued at $156,000 after buying an additional 2,453 shares during the period. Metropolitan Life Insurance Co. NY lifted its stake in BioCryst Pharmaceuticals by 407.4% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 36,971 shares of the biotechnology company’s stock valued at $298,000 after buying an additional 29,685 shares during the period. Finally, Paloma Partners Management Co acquired a new position in BioCryst Pharmaceuticals in the fourth quarter valued at approximately $84,000. 91.90% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:BCRX traded down $0.83 during midday trading on Friday, hitting $7.52. The stock had a trading volume of 391,975 shares, compared to its average volume of 847,401. BioCryst Pharmaceuticals has a 12 month low of $4.76 and a 12 month high of $9.95. The company has a current ratio of 1.65, a quick ratio of 1.62 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $895.21 million, a PE ratio of -7.67 and a beta of 1.80.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.
Read More: What are convertible shares?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.